Literature DB >> 9782238

Preservation of hearing in acoustic neuromas treated by gamma knife surgery.

J M Thomassin1, J P Epron, J Régis, C Delsanti, A Sarabian, J C Peragut, W Pellet.   

Abstract

138 acoustic schwannomas were treated by Gamma Knife surgery from July 1992 to May 1994. Cases with neurofibromatosis were excluded because of differences in the patterns of growth and development of tumors in these cases. Hearing was evaluated by tonal and vocal audiometry and classified using the Gardner and Robertson score. 104 patients were observed at 3 years after treatment. Hearing studies, the relation of tumor volume to hearing, central and marginal dose, number of shots and preoperative brain-stem-evoked responses (BER) were all recorded. 70% of patients with normal hearing maintained a useful hearing, and 50% of patients with useful hearing maintained serviceable hearing. No correlation was found between hearing preservation and tumor volume, central and marginal dose and number of shots. Gamma Knife surgery seems to be superior to microsurgery with regard to preservation of useful hearing.

Entities:  

Mesh:

Year:  1998        PMID: 9782238     DOI: 10.1159/000056409

Source DB:  PubMed          Journal:  Stereotact Funct Neurosurg        ISSN: 1011-6125            Impact factor:   1.875


  3 in total

1.  Should initial surveillance of vestibular schwannoma be abandoned?

Authors:  Sarah Eljamel; Musheer Hussain; M Sam Eljamel
Journal:  Skull Base       Date:  2011-01

2.  CT- and MRI-based gross target volume comparison in vestibular schwannomas.

Authors:  Bhudevi Soubhagya N Kulkarni; Harjot Bajwa; Mukka Chandrashekhar; Sunil Dutt Sharma; Rohith Singareddy; Dileep Gudipudi; Shabbir Ahmad; Alok Kumar; N V N Madusudan Sresty; Alluri Krishnam Raju
Journal:  Rep Pract Oncol Radiother       Date:  2017-04-22

3.  Stereotactic radiosurgery: a meta-analysis of current therapeutic applications in neuro-oncologic disease.

Authors:  Susan C Pannullo; Justin F Fraser; Jennifer Moliterno; William Cobb; Philip E Stieg
Journal:  J Neurooncol       Date:  2010-12-09       Impact factor: 4.130

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.